Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Dec;40(12):5366-5382.
doi: 10.1007/s12325-023-02644-5. Epub 2023 Oct 6.

Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Piergiacomo Calzavara-Pinton  1 , Jarmila Čelakovská  2 , Hilde Lapeere  3 , Gregor Holzer  4 , Mona Al-Ahmad  5 , Chia-Yu Chu  6 , Silvia M Ferrucci  7 , Yoko Kataoka  8 , Mariateresa Rossi  9 , Daria S Fomina  10   11 , Wen-Hung Chung  12 , Thrasyvoulos Tzellos  13 , Anne-Claire Fougerousse  14   15 , Jiangming Wu  16 , Marius Ardeleanu  17 , Zafer E Ozturk  18
Affiliations
Observational Study

Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Piergiacomo Calzavara-Pinton et al. Adv Ther. 2023 Dec.

Abstract

Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting.

Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed.

Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure.

Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments.

Clinical trial registration: ClinicalTrials.gov identifier NCT03992417. Video Abstract.

Keywords: Atopic dermatitis; Comorbidities; Disease burden; Observational study; Treatment patterns.

PubMed Disclaimer

Conflict of interest statement

Piergiacomo Calzavara-Pinton is an advisory board member for AbbVie, Almirall, Galderma, LEO Pharma, Meda and Sanofi. Jarmila Čelakovská has nothing to disclose. Hilde Lapeere is on the advisory boards of AbbVie, LEO Pharma, Eli Lilly, Pfizer and Sanofi. Gregor Holzer is an advisory board member for AbbVie, Almirall, Eli Lilly, Galderma, LEO Pharma and Sanofi. Mona Al-Ahmad is an advisory board member and speaker for AstraZeneca, GSK and Novartis. Chia-Yu Chu is an investigator for AbbVie, Dermira, Eli Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., Roche and Sanofi; a consultant for AbbVie, Eli Lilly, Novartis, Pfizer, Roche and Sanofi; a speaker for AbbVie, Eli Lilly, Mylan, Novartis, Pfizer, Roche, Sanofi and Viatris; and an advisory board member for Mylan, Pfizer, Roche and Sanofi. Silvia M. Ferrucci is an advisory board member for AbbVie, Eli Lilly and Sanofi; a Principal Investigator for Almirall, Menarini and Pfizer; and reports honoraria for lectures and research grants from Novartis. Yoko Kataoka reports lecturer honoraria from AbbVie, Pfizer and Sanofi; and research funding from AbbVie, Amgen, LEO Pharma, Lilly, Maruho, Otsuka, Pfizer, Sanofi and Taiho. Mariateresa Rossi is a speaker for AbbVie, Galderma, La Roche Posay, LEO Pharma, Pfizer and Sanofi. Daria S. Fomina reports honoraria from CSL Behring, Novartis, Sanofi and Shire. Wen-Hung Chung has nothing to disclose. Thrasyvoulos Tzellos has received honoraria from and is an advisory board member and speaker for AbbVie; and has received honoraria from and is an advisory board member for Boehringer Ingelheim and Sanofi. Anne-Claire Fougerousse is a consultant for AbbVie, Lilly and Sanofi. Jiangming Wu and Zafer E. Ozturk are employees of Sanofi and may hold stock and/or stock options in the company. Marius Ardeleanu is an employee and shareholder of Regeneron Pharmaceuticals Inc.

Figures

Fig. 1
Fig. 1
Family history of AD and other type 2 inflammatory conditions. Percentages are calculated using the number of patients in the enrollment population as the denominator. AD atopic dermatitis, EoE eosinophilic esophagitis, NSAID non-steroidal anti-inflammatory drug
See this image and copyright information in PMC

References

    1. Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75–e91. doi: 10.1111/ijd.14763. - DOI - PubMed
    1. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274–9.e3. doi: 10.1016/j.jaad.2017.04.019. - DOI - PubMed
    1. Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73(3):696–704. doi: 10.1111/all.13320. - DOI - PMC - PubMed
    1. Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013;68(4):498–506. doi: 10.1111/all.12112. - DOI - PMC - PubMed
    1. Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. doi: 10.2340/00015555-3510. - DOI - PMC - PubMed

Publication types

Substances

Associated data